Matches in Wikidata for { <http://www.wikidata.org/entity/Q80432467> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q80432467 description "artículu científicu espublizáu en xunu de 2007" @default.
- Q80432467 description "im Juni 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80432467 description "scientific article published on 01 June 2007" @default.
- Q80432467 description "wetenschappelijk artikel" @default.
- Q80432467 description "наукова стаття, опублікована в червні 2007" @default.
- Q80432467 name "Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study" @default.
- Q80432467 name "Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study" @default.
- Q80432467 type Item @default.
- Q80432467 label "Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study" @default.
- Q80432467 label "Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study" @default.
- Q80432467 prefLabel "Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study" @default.
- Q80432467 prefLabel "Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study" @default.
- Q80432467 P1433 Q80432467-BFFB15B7-E31B-41F1-B74E-505ED19A19A8 @default.
- Q80432467 P1476 Q80432467-19A210F0-E745-40DF-B0B0-983D46B55E9B @default.
- Q80432467 P2093 Q80432467-1455E47D-BD82-4896-A224-BCFE2DF6E205 @default.
- Q80432467 P2093 Q80432467-4883CDF8-CE8D-4E0B-AF23-3FC3CDFED05E @default.
- Q80432467 P2093 Q80432467-4D6E1E5E-45F6-4F3E-9D2E-ACC04BA0EC78 @default.
- Q80432467 P2093 Q80432467-54F1570D-B7C1-41E4-8877-E029ED6F94B8 @default.
- Q80432467 P2093 Q80432467-6A92E6A6-4710-451C-9D9F-B2991A9E5C58 @default.
- Q80432467 P2093 Q80432467-7406C336-2C13-4D2A-B87E-872AD2E76E84 @default.
- Q80432467 P2093 Q80432467-806820F8-5C49-40E0-94DC-78A0FC01FB16 @default.
- Q80432467 P2093 Q80432467-C393BF5B-4799-4920-BBB7-D6B2B5EAEA03 @default.
- Q80432467 P2093 Q80432467-EBA36F4D-5979-4A29-A8C1-FB064B99727C @default.
- Q80432467 P2093 Q80432467-ECF5B03C-C2FB-4605-A7CC-E8185D8485A8 @default.
- Q80432467 P304 Q80432467-7CCF1319-D8FC-4BCC-BD53-BB4F841BEF03 @default.
- Q80432467 P31 Q80432467-93900E7C-DCEA-4F95-9197-88C6975E4231 @default.
- Q80432467 P356 Q80432467-F5AC1609-22F1-4B15-ABE6-65338C11DDD0 @default.
- Q80432467 P433 Q80432467-7F157AA2-292E-4AB1-9F4F-F63103D7CBCD @default.
- Q80432467 P478 Q80432467-5815596E-E2B4-4893-8991-4A97D3934DD1 @default.
- Q80432467 P577 Q80432467-0023D080-8836-4F91-A33D-0C519A92952B @default.
- Q80432467 P698 Q80432467-4B751751-6FBD-42E5-9ED3-AA86B6E5E5EC @default.
- Q80432467 P356 J.1365-4632.2007.03158.X @default.
- Q80432467 P698 17550570 @default.
- Q80432467 P1433 Q15752742 @default.
- Q80432467 P1476 "Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study" @default.
- Q80432467 P2093 "Alan Menter" @default.
- Q80432467 P2093 "Brian Hennessey" @default.
- Q80432467 P2093 "Darryl P Toth" @default.
- Q80432467 P2093 "David M Pariser" @default.
- Q80432467 P2093 "Efalizumab Study Group" @default.
- Q80432467 P2093 "Graham Wetherill" @default.
- Q80432467 P2093 "Hoi M Leung" @default.
- Q80432467 P2093 "Marvin Garovoy" @default.
- Q80432467 P2093 "Paul Kwon" @default.
- Q80432467 P2093 "Tiffani K Hamilton" @default.
- Q80432467 P304 "637-648" @default.
- Q80432467 P31 Q13442814 @default.
- Q80432467 P356 "10.1111/J.1365-4632.2007.03158.X" @default.
- Q80432467 P433 "6" @default.
- Q80432467 P478 "46" @default.
- Q80432467 P577 "2007-06-01T00:00:00Z" @default.
- Q80432467 P698 "17550570" @default.